Therapeutic classes falling within the top 10 most utilized and costly categories had some interesting, although not altogether unsurprising, movement. View out our latest video blog which addresses some of the changes and trends seen for the top ten drug classes both in- and out-of-network.
July/August 2023 Kontos Kommentary The following commentary is produced by Tom Kontos, Chief Economist, ADESA Auctions.1
Tech leaders are feeling pressured to integrate generative artificial intelligence (GenAI) into their programs, but what do we really
Company receives 2023 Stratus Award for patented technology designed
